• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Phase III dry eye treatment study completed

Article

ProTrials Research has completed a large phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease.

 

Sunnyvale, CA-ProTrials Research has completed a large phase III clinical study examining the safety and effectiveness of a new treatment for dry eye disease.

In the last 3 years, ProTrials has conducted four phase III dry eye studies, and multiple phase III trials across a broad range of therapeutic areas involving over 100 sites and 1,000 patients, according to the company.

“ProTrials offers experience in many therapeutic areas, but our ability to handle the intricacies required in ophthalmology studies is key to our repeated success in this type of research,” said Inger Arum, president of ProTrials.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.